cyrilzakka/clinical-trials huggingface dataset:
The Effects of Core Stabilization Exercises With Swisball in Stroke Patients

Stroke is often associated with secondary complications such as nutritional and metabolic disorders, endocrine dysfunction, mental problems, and cardiopulmonary disorders caused by neurological and musculoskeletal deficits. The absence of the paretic side muscles and the difficulty of movement together with restrictive pulmonary disorders trigger a secondary decrease in cardiopulmonary function and expose insufficient energy associated with gait resulting in a decrease in asymmetric trunk exercise endurance.

Studies have shown that these patients have muscle weakness and delayed activity of trunk muscles, significant loss of trunk position sense, insufficient pressure control center while sitting, decreased trunk performance, and trunk asymmetry during walking. It has been reported that trunk function with balance and walking ability in stroke patients is a useful determinant of daily life activities, balance and walking ability. Balance disorders may be the result of changes in the sensory and integrative aspects of motor control. In the subacute phase, more than 80% of the subjects who have had stroke for the first time have an imbalance in their balance. After a stroke, upper motor neuron damage can cause unconditioned. This results in physical inactivity and decreased cardiorespiratory fitness. Respiratory muscle weakness and changes in thoraco-abdominal motion may be associated with a decrease in tidal volume and lower exercise tolerance.

Eligibility Criteria:
Inclusion Criteria:

1. Unilateral and first time stroke
2. Ability to understand and follow verbal instructions
3. Brunnstrom healing phase being above 3 for lower limbs;
4. Ability to walk 10 m distance independently, with or without a mobility assistant.
5. Patients who can sit on a stable surface for 30 seconds
6. Patients without respiratory diseases or injuries

Exclusion Criteria:

1. Neurological disorders other than stroke that could potentially affect balance and ambulation;
2. Body failure scale score below 10 points
3. Apraxia and hemineglect
4. 80 years and older
5. Orthopedic disorders or rib fracture
6. Patients with neglect syndrome
7. A history of seizures or a family history of epilepsy
Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction

Background and Objective: Acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels. The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI.

Patients are randomized to receive periinterventional intravenous BQ-123 or placebo.

Background and Objective: Acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels. We have previously shown that thrombectomy in ST-elevation myocardial infarction (STEMI) accelerates ST-segment resolution, possibly by preventing distal embolization. Therefore, we analyzed the vasoconstrictor concentration of acute coronary thrombi, and found high concentrations of endothelin (ET) which correlated with the magnitude of ST-segment resolution within one hour of percutaneous coronary intervention (PCI). Furthermore, ET-receptor blockade by tezosentan significantly repressed vasoconstriction in an in-vitro model using porcine coronary artery rings incubated with coronary thrombus homogenates extracted from STEMI patients.

The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI.

Methods: Fifty eligible patients will be randomized to receive periinterventional intravenous BQ-123 or placebo. The primary endpoint of the study will be microvascular function evaluated by cardiac magnetic resonance tomography.

Eligibility Criteria:
Inclusion Criteria:

* STEMI patients (defined as: Evidence of ischemic chest pain for \>30 minutes within \<12 hours and new ST-segment elevation for ≥2 mm in two or more contiguous electrocardiographic leads or in case of a true posterior infarction reciprocal ST-segment depressions in in V1 and V2 \>1mm and/or elevated serum creatine phosphokinase or twofold elevation of troponin-T), aged 18 years and above, who undergo primary percutaneous revascularization (PCI) and have confirmed initial TIMI 0 or 1 in the infarct related coronary artery.

Exclusion Criteria:

* Significant liver disease
* Thrombolytic therapy
* History of prior myocardial infarction
* Current atrial fibrillation
* History of congestive heart failure
* History of migraine headache
* Significant valvular heart disease, primary myocardial disease
* Cardiogenic shock (sRR \<90mmHg or need for inotropic support)
* Child-bearing potential
* Inability to read, understand and sign the informed consent
* Life expectancy \<3y
* Prior organ transplantation
* Medication with konazoles, ritonavir, rifampicin and sulfonyl-urea derivatives
* Participation in another clinical study
* Metal implants contraindicating CMR
Smart Vision Labs Autorefractor

The study is used to verify the accuracy and repeatability of Smart Vision Labs Refractor.


Eligibility Criteria:
Inclusion Criteria:

* healthy young adults
* ages 18-35 year
* male and female

Exclusion Criteria:

* presence of ocular disease
* refractive surgery
* amblyopia
Asthma Clinics Helping Expand Cost Conversations

Healthcare costs are a critical barrier to U.S. families' ability to access the preventive care needed to manage their children's asthma. Asthma specialty care teams are uniquely positioned to help families navigate these cost barriers, but lack structured approaches to discussing this sensitive and complex topic. This study will train asthma specialty care teams to identify families at risk for financial burden and engage in conversations about strategies to manage asthma care costs. The study team will evaluate the impact of a health care provider training on the frequency of cost navigation conversations. The investigators hypothesize that the health care provider training will increase the frequency of parent-reported cost conversations in the clinic.


Eligibility Criteria:
Inclusion Criteria:

Eligible caregivers will:

* attend a routine asthma care appointment for a 4-17 year old child
* screen positive for possible financial burden related to the cost of asthma care

Eligible healthcare providers will:

* be members of a pediatric asthma specialty care team

Exclusion Criteria:

Caregivers will not be eligible if they:

* attend an appointment for conditions other than routine asthma care
* do not screen positive for possible financial burden related to the cost of asthma care

Healthcare providers will not be eligible if they:

* are not part of the pediatric asthma specialty care team in the participating clinic
Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants

The main purpose of this study is to evaluate immune persistence at 30 and 36 Months of Age and Pertussis Breakthrough Infections between 19 and 36 Months of Age following two regiments of DTaP-IPV/Hib Pentavalent Vaccine in Healthy 2-Month-Old Infants and Children in China.

This study was based on the DTaP-IPV/Hib Pentavalent Vaccine Basic Immunization Strategy Optimization Study Cohort ("Pentavalent Vaccine Cohort") and the Epidemiological Investigation of Carrying Status of Pathogens Causing Acute Respiratory Infections (ARIs) in Infants and Young Children Cohort ("Pathogen Surveillance Cohort").

DTaP-IPV/Hib vaccine basic immunization strategy optimization study is a single-center, randomized, prospective and open clinical trial. The study was designed for two groups: 2, 3, 4, 18 months of age (control group) and 2, 4, 6, 18 months of age (intervention group). Subjects were randomly assigned to two groups according to the principle of informed consent. Collect basic demographic information of children and their families. The control group received 3 doses of acellular DPT vaccine at 2, 3 and 4 months of age respectively, and 1 dose at 18 months of age; The intervention group received 3 doses of acellular DPT vaccine at 2, 4 and 6 months of age respectively, and 1 dose at 18 months of age. The immunogenicity and safety were observed before and after 28 days of 3 doses of basal immunization, and after 28 days of enhanced immunization at 18 months of age.

The pathogen surveillance team included 2-month-old infants and caregivers with whom they shared a life history. After informed consent, the researchers followed up the subjects from 2 months of age to 19 months of age. The main contents of the visit are sample collection and unified questionnaire survey.

On the basis of the surveillance of ARI aged 2 to 19 months, follow-up was conducted for 17 months. During the follow-up period, ARI telephone visit was conducted twice a week. After ARI was found, pathogen sampling and testing were conducted for them (participants and their caregivers) to monitor the emergence of pertussis infection. Blood samples and throat swabs were collected at 30 and 36 months of age (caregivers were also required to take simultaneous samples), and penta vaccine immunity persistence was observed and multiple respiratory pathogens were monitored.

Eligibility Criteria:
Inclusion Criteria:

- (1)Received 4 doses of DTaP-IPV/Hib pentavalent vaccines (2) Obtained consent from the participant's caregiver and sign an informed consent form

Exclusion Criteria:

-(1) Diagnosed by a physician with a coagulation abnormality (e.g., coagulation factor deficiency, coagulopathy, platelet abnormality) (2) Any other factor considered to make participation in the trial unsuitable.
Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

The purpose of the study is to assess the safety of BMS-986259 in stable participants hospitalized for acute decompensated heart failure.


Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

* Participants currently hospitalized for acute decompensated heart failure (ADHF)
* Participants must be hemodynamically stable, as assessed by the investigator
* Men must agree to follow specific methods of contraception, if applicable, while participating in the trial
* Women participants must have documented proof that they are not of childbearing potential

Exclusion Criteria:

* Acute cardiovascular condition other than heart failure (HF) decompensation
* Cardiogenic shock at presentation to emergency room (ER) or at any time before randomization
* Recipient of ventricular assist devices or use of any cardiac extracorporeal devices, within 12 weeks of study randomization
* Participants with contraindications to vasodilator therapy such as restrictive or obstructive cardiomyopathy, severe mitral or aortic stenosis

Other protocol-defined inclusion/exclusion criteria apply
Tolerability and Potential ECG Effects After a Single Oral Dose of Pentoxyverine Citrate in Healthy Male and Female Volunteers

The primary objective of this trial was to investigate the potential effects of pentoxyverine on the ECGs of healthy subjects. A secondary objective was the exploration of safety and tolerability. Pharmacokinetics (PK) were only to be investigated if necessary for the explanation of ECG effects.


Eligibility Criteria:
Inclusion Criteria:

1. Healthy male and female subjects according to the following criteria:

   Based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)) 12-lead ECG, clinical laboratory tests
2. Age ≥21 and ≤45 years
3. Body Mass Index (BMI) ≥18.5 and ≤29.9 kg/m²
4. Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation.

Exclusion Criteria:

1. Any finding of the medical examination (including BP, PR, and ECG) deviating from normal and of clinical relevance
2. Any evidence of a clinically relevant concomitant disease
3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
4. Surgery of the gastrointestinal tract (except appendectomy)
5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
6. History of relevant orthostatic hypotension, fainting spells or blackouts.
7. Chronic or relevant acute infections
8. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
9. Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
10. Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
11. Participation in another trial with an investigational drug within two months prior to administration or during the trial
12. Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day)
13. Inability to refrain from smoking on trial days
14. Alcohol abuse (more than 60 g/day)
15. Drug abuse
16. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
17. Excessive physical activities (within one week prior to administration or during the trial)
18. Any laboratory value outside the reference range that is of clinical relevance
19. Inability to comply with dietary regimen of trial site
20. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>450 ms);
21. A history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
App Based Study on the Symptoms of Patients With Allergic Rhinitis in the Pollen Season

App-based study of allergy patients under medication in the pollen season to determine the effect of allergic rhinitis on the quality of life.

The project aims to determine the effects of rhinitis on everyday life and thereby identify the affected pathways, irrespective of age, gender or gender socioeconomic status to lead a healthy and active life.

Eligibility Criteria:
inclusion criteria patients with allergic rhinitis

exclusion criteria none
Tai Chi Intervention by Telerehabilitation

Rational : A lot of people in the province of Quebec suffer from Parkinson's disease and they are mostly vulnerable because they gradually lose their autonomy with the worsening of the disease. Physiotherapy was proven to be an effective treatment method for these patients. However, accessibility to care remains a major issue.

Objective: This project aims to establish the clinical feasibility of a Tai chi rehabilitation program through tele rehabilitation to patients suffering of Parkinson's disease.

Methodology : This pilot study will be conduct with a pre/post-test device. Therefore, to reach the objective, an evaluation will be done before the intervention and directly after the end of the 12 weeks program. Also, the obstacles encountered during the interventions will be noted in a logbook.

Benefits: This is a priority research because its aim is to develop a care system that is efficient and accessible for a target population. The results of this study will confirm the possibility to put in place a telerehabilitation program who could reach, on a larger scale, more patients suffering from Parkinson's disease.


Eligibility Criteria:
Inclusion Criteria:

* to be diagnosed with Parkinson Disease according to the " Movement Disorders Society's diagnostic criteria " for at least 3 years
* Presence of a postural instability measured by the pull test according to Movement Disorders Society-Sponsored revision scale of Unified Parkinson Disease Rating scale " (MDS-UPDRS) with a score to item 3, 12 ≥ 1,
* Have access to Internet
* Have a caregiver available during rehabilitation sessions

Exclusion Criteria:

* Have a une cognitive impairment measured by the " Mini-Mental State Examination " (MMSE), with a total score \< 24.
The Effect of Inulin in Irritable Bowel Syndrome

Purpose: This study was conducted to evaluate the effect of inulin on bowel symptoms, depression and quality of life in individuals with constipation-dominant irritable bowel syndrome. Individuals (n=34) aged 21-63 years with constipation-dominant IBS were included in the study. Individuals were divided into two groups as prebiotic group \[(n=17) (inulin/oligofructose 50/50 mixture of 4.6 g (Inulin=total 9.2 g) inulin/oligofructose 50/50 mixture twice a day)\], and placebo \[(n=17), (Maltodextrin=9.2 g)\] group. The intervention period was 8 weeks and Bristol Stool Scale, IBS-Visual Analogue Scale, IBS-Symptom Severity Score Scale (IBS-SSS), IBS-Quality of Life Scale (IBS-QoL) and Beck Depression Scale were administered to the participants at the beginning, 1st month and 2nd month. SPSS software programme was used for statistical analysis of the data. It is thought that inulin supplementation may be effective in reducing symptom severity and frequency, improving bowel function (stool frequency, consistency and transit time) and quality of life, and thus may be beneficial in individuals with constipation-predominant IBS.

In the treatment of IBS, a multimodel perspective that includes psychological support (cognitive behavioural therapy, stress management techniques, etc.) in addition to lifestyle changes (dietary changes, etc.) may be beneficial.

Eligibility Criteria:
Inclusion Criteria:

* the individuals were between 19-65 years of age
* volunteer to participate in the study
* Individuals diagnosed with IBS by a physician according to Rome IV criteria

Exclusion Criteria:

* a history of gastrointestinal surgery (except appendectomy and cholecystectomy)
* inflammatory bowel disease
* lactose malabsorption
* gastroenteritis
* celiac disease
* gastric
* duodenal ulcer
* metabolic diseases (cardiac, hepatic and renal diseases, diabetes, etc.)
* history of malignancy
* pregnancy and lactation
* use of intestinal motility
* antidepressant drugs
* involuntary body weight loss of more than 5 kg in the last 3 months
* use of dietary fibre supplements in the last 3 months
* use of antibiotics in the last 3 months
* use of prebiotic and probiotic supplements in the last 3 months.
Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease

The present study is a proof-of-concept clinical trial to test the efficacy of low doses of a repurposed anti-epileptic drug (levetiracetam) in treating memory problems in Parkinson's disease (PD). Neuroimaging techniques will be used to determine the effect of the drug on specific brain regions (hippocampal subfields). Finally, baseline brain activity of PD patients with memory problems will be compared to PD patients without memory problems and healthy older adults to determine if activity in specific brain regions (hippocampal subfields) can be used to predict memory problems in PD. This information will be useful for future clinical trials to target drugs to these brain regions.


Eligibility Criteria:
Inclusion Criteria:

* Parkinson's Disease patients with amnestic Mild Cognitive Impairment
* Parkinson's Disease patients with no memory impairment
* Healthy volunteers
* All participants must be eligible to take MRI scans

Exclusion Criteria:

* Dementia
* Contraindication to having MRI
* Bipolar disorder, Schizophrenia, Alcohol or substance abuse
* Major depression
* Suicidal Ideation
* Difficulty complying with protocol requirements
* Significant non-PD neurological disease
* Vascular dementia
* Sensitivity to levetiracetam
* Use of anticonvulsant medications
* Use of other excluded medications
* Severe renal impairment
* Clinically significant abnormalities in B12 or thyroid function test (below normative range for elderly)
* Females of childbearing potential
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer. The effects of Tarceva will be evaluated in combination with 5-fluorouracil, leucovorin, and irinotecan, with or without Bevacizumab.


Eligibility Criteria:
Subjects must fulfill all of the following criteria to be eligible for study entry:

* Signed informed consent
* At least 18 years of age
* Histologically confirmed metastatic colorectal adenocarcinoma of the colon or rectum

Resected or biopsied primary tumors or metastatic site will serve as the basis for histologic confirmation.

* Measurable disease (defined as at least one dimension \>2 cm \[\>1 cm on spiral CT scans\])
* ECOG performance status of 0 or 1
* Life expectancy \>3 months
* Use of an effective means of contraception in men and in women of childbearing potential
* Ability to comply with study and follow-up procedures
Intraoperative Pauses in Relation to Stress Assessment Among Surgeons

Intraoperative stress among the surgical team can be a threat to patient safety and good teamwork. During surgery, surgeons often work under stressful conditions. Reducing intraoperative stress for surgeons could benefit surgeons and subsequently patients. Based on the hypothesis that an intraoperative pause including a sugar-containing drink would decrease surgeon's stress levels, the aim of this study is to compare stress levels, in relation to intraoperative stress and how this is affected by a pause including a sugar-containing drink in simulated operations.

A randomized controlled cross-over trial was conducted in a simulator environment. Primary endpoint was intra-individual change in salivary cortisol between simulations with or without a pause including a sugar containing drink. Secondary endpoints were change in heart rate, change in self-perceived stress measured by the State Trait Anxiety Inventory (STAI), and experience of the intraoperative pause.

Eligibility Criteria:
Inclusion Criteria:

* Surgeon within five years of specialization with basic laparoscopic skills, able to perform an appendectomy

Exclusion Criteria:

* diabetes
* Addison's disease
* medication with steroids or medication that affect heart rate (beta-blockers, calcium antagonists, antiarrhythmics, and digitalis) Smoking